Briacell Therapeutics Corp is seeing a notable rise in its stock price after announcing a strategic partnership.
Briacell Therapeutics Corp (BCT.TO) has seen its stock price jump by 4.98% in the last trading session. This increase is largely due to the company's recent collaboration with Uneedle, which aims to improve how its lead immunotherapy candidate, Bria-IMT, is administered.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Briacell Therapeutics Corp
BCT.TO
BCT.TO
Briacell Therapeutics Corp
WealthAwesomeMarket cap
$45.76M
52W high
$20.40
52W low
$3.68
1W change
-4.50%
Beta
1.54
Analyst Price Targets
Based on analyst covering BCT
Wall Street analysts forecast BCT stock price to rise 292.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$20.00
+292.9% Upside
Current Price
C$5.09
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BCT's historical volatility
30-Day Vol
60.0%
Annualized
90-Day Vol
87.6%
Annualized
Trend (90d)
-0.8%
Annualized drift
90d Mean
C$5.08
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$5.09 | C$4.13 โ C$6.25 |
| 60 trading days | C$5.08 | C$3.79 โ C$6.81 |
| 90 trading days | C$5.08 | C$3.55 โ C$7.26 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should think about what Briacell's partnership with Uneedle means, as it could lead to more efficient drug delivery and potentially speed up the commercialization of Bria-IMT.
Briacell Therapeutics Corp stock rises 4.98% today
The company's market cap is now around CA$40.98 million, reflecting growing investor confidence following the partnership announcement.
Bull case
The partnership with Uneedle could make administering Bria-IMT easier and more patient-friendly, which might help it gain acceptance in the market.
Bear case
Despite the positive news, the stock is still volatile. The success of the partnership depends on getting regulatory approvals and the results of ongoing clinical trials.
Partnership with Uneedle
Briacell's collaboration with Uneedle focuses on using scalable microneedle technology for Bria-IMT, aiming to enhance patient experience and treatment efficiency. This innovative approach is currently being tested in the company's pivotal Phase 3 study for advanced metastatic breast cancer.
Market Reaction
The market reacted positively to the news, with Briacell's stock closing at CA$4.64. Investors are hopeful about the potential for better drug delivery methods, which could lead to greater acceptance of Bria-IMT in the medical community.
Looking Ahead
As Briacell continues its clinical trials and partnership developments, investors should keep an eye on regulatory updates and trial results. The success of Bria-IMT could significantly influence the company's future and stock performance. For more details, visit the BCT.TO stock page.
Advertisement
